Dabigatran etexilate

(Pradaxa®)

Dabigatran etexilate

Drug updated on 10/23/2023

Dosage FormCapsule (oral: 75mg, 110 mg, 150 mg)
Drug ClassDirect thrombin inhibitor
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • To reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation.
  • For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in adult patients who have been treated with a parenteral anticoagulant for 5-10 days.
  • To reduce the risk of recurrence of DVT and PE in adult patients who have been previously treated
  • For the prophylaxis of DVT and PE in adult patients who have undergone hip replacement surgery.
  • For the treatment of venous thromboembolic events (VTE) in pediatric patients 8 to less than 18 years of age who have been treated with a parenteral anticoagulant for at least 5 days.
  • To reduce the risk of recurrence of VTE in pediatric patients 8 to less than 18 years of age who have been previously treated.

Product Monograph / Prescribing Information

Document TitleYearSource
Pradaxa (dabigatran etexilate) Prescribing Information.2021Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines